Metformin mitigates gastrointestinal radiotoxicity and radiosensitises P53 mutation colorectal tumours via optimising autophagy-Reference-Cited by-同舟云学术

Metformin mitigates gastrointestinal radiotoxicity and radiosensitises P53 mutation colorectal tumours via optimising autophagy

Published:2020-07-08 Issue:17 Volume:177 Page:3991-4006
ISSN:0007-1188
Container-title:British Journal of Pharmacology
language:en
Short-container-title:Br J Pharmacol

Author:

Chen Long¹,Liao Fengying¹,Jiang Zhongyong¹,Zhang Chi¹,Wang Ziwen¹,Luo Peng¹,Jiang Qingzhi¹²,Wu Jie¹,Wang Qing¹²,Luo Min¹³,Li Xueru⁴,Leng Yu⁴,Ma Le¹,Shen Gufang¹,Chen Zelin¹,Wang Yu¹,Tan Xu¹,Gan Yibo¹,Liu Dengqun¹,Liu Yunsheng¹,Shi Chunmeng¹^ORCID

Affiliation:

1. State Key Laboratory of Trauma, Burns and Combined Injury, Institute of Rocket Force Medicine Third Military Medical University (Army Medical University) Chongqing China

2. Institute of Clinical Medicine Southwest Medical University Luzhou China

3. Department of Toxicology, Key Laboratory of Environmental Pollution Monitoring and Disease Control, Ministry of Education Guizhou Medical University Guiyang China

4. Department of Ophthalmology The Third Affiliated Hospital of Chongqing Medical University (Gener Hospital) Chongqing China

Funder

National Basic Research Program of China

Publisher

Wiley

Subject

Pharmacology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/bph.15149

Reference65 articles.

1. Differences in p53 status significantly influence the cellular response and cell survival to 1,25-dihydroxyvitamin D3-metformin cotreatment in colorectal cancer cells

2. Goals and practicalities of immunoblotting and immunohistochemistry: A guide for submission to the British Journal of Pharmacology